Shares of Crispr Therapeutics AG climbed about 3.0% in pre-open trading after two institutional analysts published fresh coverage and ratings that gave investors a clear, company-specific reason to buy ahead of the session. Morgan Stanley initiated coverage with an Equalweight rating and set a $60 price target, a level the bank noted sits materially above where the stock had been trading. On the same morning, Mizuho Securities issued a Buy rating, giving CRSP two fresh institutional endorsements before markets opened.
Morgan Stanley framed Crispr as a "show-me" story, offering explicit near- and long-term projections for the company’s lead therapy, Casgevy. The firm forecast Casgevy sales of $327 million in 2026 and estimated peak sales on the order of $3 billion by 2035. Alongside those revenue assumptions, Morgan Stanley outlined a path to profitability by 2029. These forecasts and the $60 target have become a prominent reference point for investors evaluating the stock.
The analyst moves arrive against a backdrop of sustained Wall Street attention toward the CRISPR-focused biotech. In the weeks leading up to these reports, Citi, Evercore ISI, Bank of America, and Bernstein had either raised price targets or sustained high Buy-equivalent ratings, indicating a generally constructive stance across multiple brokerages. That continued positive tilt from the sell side has kept the stock on investors’ radars.
Beyond analyst sentiment, investors also have an identifiable clinical catalyst on the horizon. Crispr is expected to report Phase 1b data from its CTX310 cardiovascular program in the second half of 2026, providing a concrete regulatory and clinical milestone that market participants can use to assess program progress. The company also reported that it has approximately $2.44 billion in cash, which offers a substantial cash runway and offsets ongoing net losses for the time being.
The move in CRSP was notable given the broader market backdrop. Major U.S. indices were under pressure on the same day, with the S&P 500 down 1.6%, the Dow Jones Industrial Average off 1.9%, and the NASDAQ declining 2.0%. That market-wide weakness highlights that CRSP’s pre-market gain was driven by firm-level developments rather than a general risk-on environment. Peer gene-editing companies Intellia Therapeutics and Beam Therapeutics did not post comparable positive news that day.
In sum, the combination of Morgan Stanley’s inaugural coverage with a $60 target and Mizuho’s Buy rating provided investors a company-specific rationale to step into Crispr stock despite a challenging macro environment. Those analyst actions established a near-term valuation benchmark and amplified existing favorable sentiment from other research desks.
Key context: Analyst coverage and ratings from Morgan Stanley and Mizuho; Morgan Stanley projections for Casgevy sales in 2026 and at peak; expected CTX310 Phase 1b data in H2 2026; approximately $2.44 billion in cash on hand; broader U.S. indices were down on the day.